Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene FGFR1
Variant D90V
Impact List missense
Protein Effect no effect - predicted
Gene Variant Descriptions FGFR1 D90V lies within the Ig-like C2-type domain 1 of the Fgfr1 protein (UniProt.org). D90V has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr1 in cultured cells (PMID: 29533785), and therefore, is predicted to have no effect on Fgfr1 protein function.
Associated Drug Resistance
Category Variants Paths

FGFR1 mutant FGFR1 D90V

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_023110.3
gDNA chr8:g.38429771T>A
cDNA c.269A>T
Protein p.D90V
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_017013221.1 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_017013221 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_023110 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001174063.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_006716307.1 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_017013221.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_006716304 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_017013222 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001174065 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_017013223 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_023110.3 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_015850.3 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_015850.4 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001174063.1 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001174065.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001354369.1 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_006716303.3 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_047421569.1 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_017013225.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001410922.1 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_017013225.3 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001174065.1 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_006716307.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_006716306 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001354367.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_047421570.1 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_017013222.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_006716303.4 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_006716304.1 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_023110.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_017013224.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001174063 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_015850 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_017013224 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001354369.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_006716303 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_006716304.2 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_006716307 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
XM_017013225 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38
NM_001354367.1 chr8:g.38429771T>A c.269A>T p.D90V RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR1 mutant Advanced Solid Tumor predicted - sensitive Erdafitinib Case Reports/Case Series Actionable In a Phase II trial (MATCH), Balversa (erdafitinib) treatment resulted in an objective response rate of 16% (4/25), median progression-free survival of 3.6 months, and median overall survival of 11.0 months in patients with advanced solid tumors harboring FGFR1, FGFR2, or FGFR3 mutations or fusions (PMID: 38603650; NCT02465060). 38603650
FGFR1 mutant transitional cell carcinoma predicted - sensitive Erdafitinib Phase II Actionable In a Phase II trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 42% (40/96, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (J Clin Oncol 36, 2018 (suppl; abstr 4503); NCT02365597). detail...
FGFR1 mutant Advanced Solid Tumor predicted - sensitive ICP-192 Phase I Actionable In a Phase I trial, ICP-192 (gunagratinib) was well-tolerated, and resulted in an overall response rate or 33.3% (4/12, 1 complete response, 3 partial response) and a disease control rate of 91.7% (11/12) in patients with advanced solid tumors harboring FGF/FGFR gene aberrations (J Clin Oncol 39, 2021 (suppl 15; abstr 4092); NCT03758664). detail...
FGFR1 mutant Advanced Solid Tumor predicted - sensitive Debio 1347 Phase I Actionable In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297). 30745300
FGFR1 mutant Advanced Solid Tumor sensitive Pemigatinib Preclinical - Cell line xenograft Actionable In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to Pemazyre (pemigatinib) in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771). detail...